Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Exclusion Criteria

• •1. Disease progression involving the central nervous system (CNS) or transformation to another histology
• •2. Intervening chemotherapy, immunotherapy, or investigational agent specifically to treat CLL if administered before date of IRC confirmed progressive disease
• •3. In the 4 weeks before dosing: radiation therapy, major surgery, or receipt of an investigational drug
• •4. Requirement for treatment with a strong CYP3A inhibitor
• •5. Uncontrolled systemic infection or requirement for IV antibiotics
• •6. Noncompliance on the parent study(PCYC-1115-CA)